Germline and somatic testing for prostate cancer can improve outcomes and promote early detection and prevention, yet many patients are not aware of testing and the impact it can have on treatment options.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Germline and somatic testing for prostate cancer can improve outcomes and promote early detection and prevention, yet many patients are not aware of testing and the impact it can have on treatment options. In this episode, CANCER BUZZ speaks with David Gill, MD, medical oncologist at Intermountain Healthcare’s Intermountain Cancer Center and Lindsey Byrne, MS, LCGC, licensed certified genetic counselor at The Ohio State University Comprehensive Cancer Center, who discuss how genetic counselors and increased patient education can help cancer programs close the practice gap and promote guideline-concordant testing among patients diagnosed with prostate cancer.
“I’d really advocate—even in your patients with a negative NGS panel—please still consider getting germline testing in those patients.” –David Gill, MD
“We know that individuals, yes, they’re dealing with a diagnosis of cancer, but the first thing people say to me when I sit down with them is, ‘All right, I have this figured out, but what does this mean for my family?’ They’re really worried about their family, and that’s where our focus is, to help take care of that.”—Lindsey Byrne, MS, LCGC
Guests:
David Gill, MD
Medical Oncologist
Intermountain Healthcare - Intermountain Cancer Center
Salt Lake City, Utah
Lindsey Byrne, MS, LCGC
Licensed Certified Genetic Counselor
The Ohio State University Comprehensive Cancer Center – The James
Columbus, Ohio
This episode was developed in connection with the ACCC education program Germline and Somatic Testing for Mutations to Optimize Outcomes in Metastatic Prostate Cancer and is supported by AstraZeneca, Johnson & Johnson, and Pfizer.
Resources:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
July 8, 2026
June 30, 2026
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
